> Details

Saouli, Amine; Ruffion, Alain; Dariane, Charles; Barret, Eric; Fiard, Gaëlle; Hankard, Gaelle Fromont; Créhange, Gilles; Roubaud, Guilhem; Beauval, Jean Baptiste; Brureau, Laurent; Renard-Penna, Raphaëlle; Gauthé, Mathieu; Baboudjian, Michael; Ploussard, Guillaume; Rouprêt, Morgan

Salvage Radical Prostatectomy for Recurrent Prostate Cancer: A Systematic Review (French ccAFU)

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Salvage Radical Prostatectomy for Recurrent Prostate Cancer: A Systematic Review (French ccAFU)
  • Contributor: Saouli, Amine; Ruffion, Alain; Dariane, Charles; Barret, Eric; Fiard, Gaëlle; Hankard, Gaelle Fromont; Créhange, Gilles; Roubaud, Guilhem; Beauval, Jean Baptiste; Brureau, Laurent; Renard-Penna, Raphaëlle; Gauthé, Mathieu; Baboudjian, Michael; Ploussard, Guillaume; Rouprêt, Morgan
  • Published: MDPI AG, 2023
  • Published in: Cancers, 15 (2023) 22, Seite 5485
  • Language: English
  • DOI: 10.3390/cancers15225485
  • ISSN: 2072-6694
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: The aim of this study was to systematically review the current evidence regarding the oncological and functional outcomes of salvage radical prostatectomy (sRP) for recurrent prostate cancer. A systematic review was conducted throughout September 2022 using the PubMed, Science Direct, Scopus, and Embase databases. Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines were followed to identify eligible studies. A total of 55 studies (3836 patients) met our eligibility criteria. The vast majority of men included had radiation therapy (including brachytherapy) as their first-line treatment (n = 3240, 84%). Other first-line treatments included HIFU (n = 338, 9%), electroporation (n = 59, 2%), proton beam therapy (n = 54, 1.5%), cryotherapy (n = 34, 1%), focal vascular targeted photodynamic therapy (n = 22, 0.6%), and transurethral ultrasound ablation (n = 19, 0.5%). Median preoperative PSA, at the time of recurrence, ranged from 1.5 to 14.4 ng/mL. The surgical approach was open in 2300 (60%) cases, robotic in 1465 (38%) cases, and laparoscopic in 71 (2%) cases. Since 2019, there has been a clear increase in robotic versus conventional surgery (1245 versus 525 cases, respectively). The median operative time and blood loss ranged from 80 to 297 min and 75 to 914 mL, respectively. Concomitant lymph node dissection was performed in 2587 cases (79%). The overall complication rate was 34%, with a majority of Clavien grade I or II complications. Clavien ≥ 3 complications ranged from 0 to 64%. Positive surgical margins were noted in 792 cases (32%). The median follow-up ranged from 4.6 to 94 months. Biochemical recurrence after sRP ranged from 8% to 51.5% at 12 months, from 0% to 66% at 22 months, and from 48% to 59% at 60 months. The specific and overall survival rates ranged from 13.4 to 98% and 62 to 100% at 5 years, respectively. Urinary continence was maintained in 52.1% of cases. sRP demonstrated acceptable oncological outcomes. These results, after sRP, are influenced by several factors, and above all by pre-treatment assessment, including imaging, with the development of mpMRI and metabolic imaging. Our results demonstrated that SRP can be considered a suitable treatment option for selected patients, but the level of evidence remains low.
  • Access State: Open Access